000 | 02442cam a22004218i 4500 | ||
---|---|---|---|
001 | 20339 | ||
003 | OSt | ||
005 | 20241112135457.0 | ||
008 | 240213s2024 nju 001 0 eng | ||
020 |
_a9781119822981 _q(paperback) |
||
020 |
_z9781119823018 _q(Adobe PDF) |
||
020 |
_z9781119823025 _q(epub) |
||
040 |
_aDNLM/DLC _beng _erda _cDLC _dDLC _dIQ-MoCLU |
||
060 | 0 | 0 | _aWM 402 |
082 | 0 | 0 |
_a616.89/18 _223 _bH816 |
100 | 1 |
_aHorowitz, Mark, _eauthor. |
|
245 | 1 | 4 |
_aThe Maudsley deprescribing guidelines : _bantidepressants, benzodiazepines, gabapentinoids and z-drugs / _cMark Horowitz, David Taylor. |
246 | 1 | _aDeprescribing guidelines in psychiatry | |
263 | _a | ||
264 | 1 |
_aHoboken, NJ : _bWiley-Blackwell, _c2024. |
|
300 |
_apages 568; _billustrations: _c25 cm |
||
336 |
_atext _btxt _2rdacontent |
||
337 |
_aunmediated _bn _2rdamedia |
||
338 |
_avolume _bnc _2rdacarrier |
||
500 | _aIncludes index. | ||
520 | _a"The term 'deprescribing' originates from geriatric medicine where polypharmacy in frail patients can cause more harm than benefit.1 Deprescribing is increasingly recognised to be a key component of good prescribing - reducing doses when they are too high, and stopping medications when they are no longer needed.2 This process cannot occur in a vacuum of theoretical concerns but should take into account the patient's health, current level of functioning and, importantly, their values and preferences.1 Deprescribing seeks to apply best practice in prescribing to the process of stopping a medication. It requires the same skill and experience as for the process of prescribing from prescribers, as well as support from pharmacists and other healthcare staff to get the best results. Importantly, it should place patients at the centre of the process to ensure medicines optimisation"-- | ||
650 | 1 | 2 |
_aMental Disorders _xdrug therapy |
650 | 1 | 2 | _aDeprescriptions |
650 | 2 | 2 |
_aPsychotropic Drugs _xadministration & dosage |
650 | 2 | 2 |
_aPolypharmacy _xprevention & control |
650 | 2 | 2 |
_aDrug-Related Side Effects and Adverse Reactions _xprevention & control |
655 | 2 | _aPractice Guideline | |
700 | 1 |
_aTaylor, David, _d1963- _eauthor. |
|
776 | 0 | 8 |
_iOnline version: _aHorowitz, Mark. _tMaudsley deprescribing guidelines in psychiatry _dHoboken, NJ : Wiley-Blackwell, 2024 _z9781119823018 _w(DLC) 2024007104 |
910 | _aASEEL | ||
942 |
_2ddc _n0 _cBK |
||
999 |
_c20339 _d20339 |